Home > Careers > Training Programmes: IMMUTRAIN

IMMUTRAIN: Training Network for the Immunotherapy of Cancer


Funded by Marie Skłodowska-Curie Programme, H2020.

In the European Union, cancer is the leading cause of death and the overall cancer incidence is still increasing. As a result of expanding efforts to improve cancer outcome, a main paradigm change is occurring in cancer therapy towards individualized medicine. Antibody-based therapies form an integral and constantly growing part of this approach. Antibody-based therapies will strongly influence the coming decade of cancer care. Accordingly the need for well-trained and skilled researchers in academia and industry is dramatically increasing in this field.

IMMUTRAIN is a training network bringing together experts in the fields of monoclonal antibodies, dendritic cells, T-cells and immunomodulatory nucleic acids with a considerable industrial involvement. The network comprises 9 academic research groups (CNIO is one of them) and 5 industrial partners in of seven European countries. IMMUTRAIN promotes young researchers to match the challenges of immunotherapies. Particular focus is placed on combinatorial therapies and on the new emerging field of bispecific antibodies used to target both the tumor and the patient´s immune system.

Call for applications:

The IMMUTRAIN program is looking for 15 Early Stage Researchers (ESR) to join the training and research program. IMMUTRAIN offers a three years training program in the immunotherapy of cancer with the possibility of earning a doctoral degree (PhD or equivalent) at any of the participating host institutions.

The Melanoma Group at the CNIO offers two positions for early stage researchers interested in the identification and validation of anticancer agents with a triple mode of action: (i) induction of tumor cell death, (ii) movilization of the immune system for tumor cell attack and clearance, and (iii) inhibition of the abnormal vasculature that supports metastatic development. These studies will be performed in the context of a multidisciplinary team that involves specialists in molecular oncology, nanotechnology, pharmacology, dermatology and pathology, with the ultimate objective of developing new treatments for clinical testing.

Deadline for applications: March 4th, 2016.